Company News »

Tokai Pharmaceuticals Reports Third Quarter 2014 Financial Results

Business Wire
Share on StockTwits
Published on

Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) , a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today reported company highlights and financial results for the quarter ended September 30, 2014.

“This has been an exciting year for Tokai, both operationally and in the clinic,” stated Jodie Morrison, president and chief executive officer at Tokai. “We successfully completed our initial public offering, strengthened our balance sheet and made great progress with our lead product candidate, galeterone, for the potential treatment of patients with castration resistant prostate cancer. Over the last year we have refined our initial registration strategy to focus on advancing galeterone into late-stage development in patients with androgen receptor splice variants that are expected to show poor response to currently available secondary hormonal treatment options, with plans to initiate a pivotal Phase 3 clinical trial, ARMOR3-SV, in the first half of 2015. In addition, we committed to deepening our pipeline, including advancing our Androgen Receptor Degrading Agents program. We look forward to reporting key updates on these efforts as we go forward.”

Recent Business Highlights

  • Completed Initial Public Offering (IPO): On September 23, 2014, Tokai announced that it had completed its IPO of common stock raising $97.2 million, before underwriting discounts and commissions and offering expenses. Subsequent to the close of the quarter, Tokai completed the sale of an additional 540,000 shares pursuant to the underwriters’ partial exercise of their option to purchase additional shares, resulting in additional gross proceeds of $8.1 million.
  • Reported Interim Results from Ongoing ARMOR2 Trial: At the European Society for Medical Oncology (ESMO) 2014 congress, data presented from ARMOR2, the company’s ongoing Phase 2 clinical trial evaluating galeterone as a treatment for patients with castration resistant prostate cancer (CRPC), demonstrated clinically meaningful reductions in prostate-specific antigen (PSA) levels, a marker of prostate cancer growth. Expanded clinical data in patients with C-terminal loss as well as additional preclinical data were also presented, providing further support for galeterone’s potential activity in CRPC patients whose tumors express androgen receptor (AR) splice variants, which are believed to be associated with resistance to hormonal agents commonly used to treat CRPC patients.
  • Strengthened Leadership Team: During the third quarter of 2014, Tokai announced the appointment of Lee Kalowski as Chief Financial Officer and Daniel Dransfield, Ph.D. as Vice President, Head of Translational Medicine.

Financial Results

  • Cash and cash equivalents as of September 30, 2014 were $105.5 million compared to $31.8 million at December 31, 2013.
  • Research and development (R&D) expenses were $2.8 million in the third quarter of 2014 compared to $2.7 million in the third quarter of 2013.
  • General and administrative (G&A) expenses were $3.6 million in the third quarter of 2014 compared to $0.7 million in the third quarter of 2013. G&A expenses in the third quarter of 2014 included a one-time fee of $1.1 million paid to a financial advisor upon the closing of the company’s IPO in connection with strategic and financial advisory services unrelated to the IPO. G&A expenses in the third quarter of 2014 also included a one-time stock-based compensation charge of $0.9 million related to the acceleration of vesting of options upon the closing of the Company’s IPO.
  • Net Loss was $6.4 million in the third quarter of 2014 compared to a net loss of $3.4 million in the third quarter of 2013.

Upcoming Activities

  • Clinical Update: Updated interim results from ARMOR2 will be presented in an oral presentation at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain on Wednesday, November 19, 2014.
  • Corporate Presentations: Tokai management will present at the 2014 Credit Suisse Healthcare Conference in Phoenix, Arizona on Tuesday, November 11, 2014 at 9:30 a.m. (ET) and at the Stifel 2014 Healthcare Conference in New York City on Tuesday, November 18, 2014 at 8:35 a.m. (ET). Live webcasts of these presentations can be accessed under the “Calendar of Events” page within the Investors & Media section of the company’s website at Replays of the webcasts will be archived on the Tokai website for two weeks following the date of the presentation.

About Tokai Pharmaceuticals

Tokai Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases. The company’s lead drug candidate, galeterone, is a highly selective, multi-targeted, oral small molecule drug candidate being developed for the treatment of patients with castration-resistant prostate cancer. The company’s Androgen Receptor Degrading Agents (ARDA) drug discovery program is focused on the identification and evaluation of compounds that are designed to disrupt androgen receptor signaling through enhanced androgen receptor degradation and are targeted to patients with androgen receptor signaling diseases, including prostate cancer. For more information on the company and galeterone, please visit

Forward-looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, intellectual property, cash resources, financial position and projected costs, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether the Company’s cash resources will be sufficient to fund the Company’s continuing operations for the period anticipated; whether data from early clinical trials will be indicative of the data that will be obtained from future clinical trials; whether the Company can establish companion diagnostics arrangements for its planned Phase 3 trial; whether galeterone will advance through the clinical trial process on the anticipated timeline and warrant submission for regulatory approval; whether such a submission would receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies on a timely basis or at all; whether, if galeterone obtains such approval, it will be successfully distributed and marketed; and other factors discussed in the “Risk Factors” section of the Company’s Registration Statement on Form S-1. In addition, the forward-looking statements included in this press release represent the Company’s views as of November 10, 2014. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to November 10, 2014.

(in thousands, except share and per share information)
Three Months Nine Months
Ended Ended
September 30, September 30,
2014 2013 2014 2013
Revenue $ $ $ $
Operating expenses:
Research and development 2,825 2,704 10,773 7,852
General and administrative 3,599 661 6,428 2,348
Total operating expenses 6,424 3,365 17,201 10,200
Loss from operations (6,424) (3,365) (17,201) (10,200)
Other income (expense), net 34 113
Net loss (6,390) (3,365) (17,088) (10,200)
Accretion of redeemable convertible preferred stock to redemption value (79)
Net loss attributable to common stockholders (6,390) (3,365) (17,088) (10,279)
Basic and diluted net loss per share $ (2.71) $ (6.82) $ (15.19) $ (26.36)
Basic and diluted weighted average number of common shares outstanding 2,357,236 493,299 1,124,627 390,001
(in thousands)
September 30, December 31,
2014 2013
Cash and cash equivalents $ 105,464 $ 31,753
Total current assets 106,724 32,178
Working capital 101,352 29,969
Total assets 106,983 32,287
Total stockholders’ equity (deficit) 101,611 (55,267)

Share on StockTwits